The ROE as of November 2024 (TTM) for Apellis Pharmaceuticals, Inc. (APLS) is -103.92%

According to Apellis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -103.92%. This represents a change of 281.66% compared to the average of -27.23% of the last 4 quarters.

Apellis Pharmaceuticals, Inc. (APLS) Historical ROE (quarterly & annually)

How has APLS ROE performed in the past?

The mean historical ROE of Apellis Pharmaceuticals, Inc. over the last ten years is -254.71%. The current -103.92% ROE has changed -59.20% with respect to the historical average. Over the past ten years (40 quarters), APLS's ROE was at its highest in in the September 2021 quarter at 341.16%. The ROE was at its lowest in in the March 2021 quarter at -355.53%.

Apellis Pharmaceuticals, Inc. (APLS) ROE by Quarter and Year

Discovering the peaks and valleys of Apellis Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Apellis Pharmaceuticals, Inc. (APLS) Average ROE

How has APLS ROE performed in the past?

The current ROE of Apellis Pharmaceuticals, Inc. (APLS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Apellis Pharmaceuticals, Inc. (APLS) ROE vs. Peers

How is APLS’s ROE compared to its peers?

Apellis Pharmaceuticals, Inc.’s ROE is greater than Prometheus Biosciences, Inc. (-31.12%), greater than Akero Therapeutics, Inc. (-32.52%), greater than Immunovant, Inc. (-56.40%), greater than Madrigal Pharmaceuticals, Inc. (-71.78%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Mirati Therapeutics, Inc. (-40.45%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Mereo BioPharma Group plc (-69.11%), greater than Blueprint Medicines Corporation (-47.66%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than Acumen Pharmaceuticals, Inc. (-32.99%),

Build a custom stock screener for Apellis Pharmaceuticals, Inc. (APLS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Apellis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Apellis Pharmaceuticals, Inc. (APLS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Apellis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.